Cerecor Inc. is a clinical-stage biopharmaceutical company focused on developing innovative drugs to make a difference in the lives of patients afflicted by neurological and psychiatric diseases. By applying our extensive knowledge and experience of neurological and psychiatric diseases and medications to treat them (“neuro-psychiatric drugs”), we have developed a systematic process to identify and advance compounds for underserved segments of common diseases and design clinical trials with the latest technologies to improve the signal-to-noise ratio and likelihood of trial success. Our process includes seeking candidates for which human proof-of-concept has been demonstrated for the compound or target and biomarkers have been identified to guide development. Learn More


October 15, 2015

Cerecor Announces Pricing of Initial Public Offering

Read More

September 3, 2015

Cerecor Initiates Phase 2 Study for CERC-301, and Antidepressant Product Candidate with Potential for Rapid Onset of Effect

Read More